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Assessing Tumor Genomic Profiling Reports 
for Genetic Counseling Referral Indications 
 
Abstract 
 Our purpose is two-fold: (1) to identify patients who may benefit from referrals to 
cancer genetic counseling by characterizing the alterations reported in tumor profiling reports 
without matched germline control, and (2) to assess the utility of public database ClinVar in 
providing further information on these alterations. We assessed 160 reports across 66 tumor 
types. 127 (79%) reports had a mutation in 1 of 86 selected cancer predisposition genes. Of 
these, 29 (23%) did not meet ACMG/NSGC criteria for referral based on tumor type alone. 
19% of mutations in selected genes were found in ClinVar, with 15% reported as both 
germline and on the pathogenic spectrum. 31% of VUSs in selected genes were found in 
ClinVar, with 2% reported as both germline and on the pathogenic spectrum. Our results 
highlight a potential to miss patients at increased risk of cancer predisposition syndromes 
based on tumor type alone. 
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 Problem Statement & Significance 
 In recent years, genomic profiling of tumors has become an increasingly common 
tool by which oncologists determine customized treatment options for patients (Zhao et al., 
2015). Treatments are primarily designed to target somatic mutations – or mutations acquired 
after conception – but the technology also has the ability to detect germline mutations – or 
mutations present since conception. Despite significant advances in technology, it remains 
difficult with solely a tumor sample to differentiate between somatic and germline mutations. 
As a result, germline mutations detected by this testing methodology are often reported 
without differentiation. This poses a problem for patients and clinicians alike, as germline 
mutations have the potential to be associated with hereditary cancer predisposition 
syndromes, affecting both the patient and his or her family members. This study aims to 
characterize the significance of mutations observed in tumor profiling results and to describe 
instances where follow-up referrals for genetic counseling would be recommended based on 
tumor profiling results. This study also aims to explore the clinical utility of public database 
ClinVar in determining whether tumor profiling companies call mutations differently than 
other sources that perform germline testing. 
 Background & Context for Literature Review 
 Over 10,000 tumor genomes have been sequenced in research or clinical settings to 
date (Wang et al., 2015). Increased availability of tumor profiling data has enabled 
researchers and oncologists to detect patterns in tumor development, as well as relationships 
between tumor genotypes and responses to various drug treatments. However, the majority of 
this complex data has yet to be fully understood, and to date, tumor profiling research has 
4 
 
been treatment-oriented and focused largely on somatic alterations (Meric-Bernstam et al., 
2016; Schrader et al., 2015). This study aims to expand our understanding of the importance 
of considering germline mutation risk detection and prevention in the setting of tumor 
profiling. 
Literature Review 
 Genetic Heterogeneity of a Tumor 
 Part of the challenge in treating tumors is due to their heterogeneous genetic makeup. 
An individual tumor may have a few to hundreds of alterations and each of these alterations 
may be present in only a few to all of the cells throughout the tumor itself (Wang et al., 
2015). For example, about half of all solid tumors studied have undergone a duplication 
event, resulting in the presence of aneuploidy in a percentage of these tumors’ cells: the later 
the duplication event in the process of tumorigenesis, the smaller the percentage of cells with 
that aneuploidy (Wang et al., 2015). 
 Tumor Development and Technological Advancements 
 It takes time for a tumor to develop the genetic alterations needed to turn non-
malignant cells into a malignant disease. In the earliest stages of tumorigenesis, there are 
fewer alterations present, and only one cell has notable mutations. This cell, according to 
Novell’s theory of tumor development put forth in 1976, continues to replicate over time, 
producing “clones” (or cell populations) with varying amounts and degrees of mutations 
(Wang et al., 2013). These clones competitively replicate, until one of the clones gains a 
sufficient number of mutations to achieve a significantly faster replication rate than the 
others. As a result, this clone grows to dominate the overall tumor cell population and propel 
it toward a cancerous state. This theory has evolved through continued research, and it is now 
5 
 
suspected that a tumor may begin with multiple clones, further contributing to the tumor’s 
genetic heterogeneity and complexity (Wang et al., 2013). 
 Tumorigenesis may be described in greater depth using colorectal cancer (CRC) as a 
model, due to its somewhat predictable course. CRC develops sequentially, from dysplasia of 
epithelium cells that progress to benign adenomas, to invasion of local tissues and metastasis 
(Fearnhead, Wilding, & Bodmer, 2002). Genetically, CRC develops through the activation 
and inactivation of oncogenes and tumor suppressor genes, respectively. There are several 
main genes involved in this process: the APC tumor suppressor gene, the RAS oncogene, and 
the TP53 gene involved in controlling the death of tumor cells (Knudson, 2001). An 
individual may be born with mutations (germline mutations) in these genes, thereby 
inheriting a cancer predisposition syndrome, and/or acquire mutations (somatic mutations) 
throughout his or her life. From genetic studies of serial biopsies, it is possible to distinguish 
the stages of CRC development through the characteristic somatic mutations that occur in 
each stage. For example, somatic mutations in the APC gene tend to occur in early stages 
while TP53 mutations tend to occur later (De la Chapelle, 2004). A five-hit hypothesis of the 
genetic basis of colorectal tumor development has been proposed consisting of two APC 
gene mutations (presumably one in each copy of the gene), followed by one RAS gene 
mutation and finally two TP53 mutations (one in each copy of the gene) (Knudson, 2001). 
 Driver Mutations Versus Passenger Mutations 
 Some tumor mutations are more aggressive than others. Vogelstein et al. (2013) 
describes driver mutations as mutations that “confer a selective growth advantage to the 
tumor cell” and passenger mutations as ones that have “no direct or indirect effect on the 
selective growth advantage of the cell” (p. 1548-1549). It is the driver mutations that speed 
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the tumor to develop at a faster rate and truly propel it toward malignancy, making these 
mutations the target of treatment attempts. However, identifying driver mutations can be very 
challenging due to a variety of complicating factors, including: the presence of many 
passenger mutations that require distinction from the driver mutation(s); the fact that the 
collective effects of a group of passenger mutations can alter cancer progression, therefore 
mimicking a driver mutation; a lack of driver mutations in the section of the tumor that is 
being sequenced; the presence of both driver and passenger mutations within the same gene; 
and the fact that driver and passenger mutations may even switch roles (Zhang et al., 2014). 
In this last regard, it is possible that a driver mutation may be attacked by a targeted cancer 
treatment at some point, allowing a passenger mutation that is resistant to the treatment to 
take over (Zhang et al., 2014). All of these factors can add complexity to the hunt for a 
tumor’s driver mutations. 
 Tumor Profiling Landscape Today 
 Tumor profiling is treatment-oriented, meaning that identifying driver mutations to 
inform personalized care is the primary goal. There are several panels currently available that 
sequence 200-500 cancer-related genes and detect base substitutions, short indels, CNVs, and 
selected fusions (Frampton et al., 2013). In general, a mutation must be present in greater 
than 10% of the tumor sample to be detected (Miller, 2012). Most of these panels, including 
Foundation Medicine’s FoundationOne cancer panel – the data from which are used in this 
study – eliminate germline mutations to narrow the focus of the test (Fang et al., 2014; 
FoundationOne, 2014). Foundation Medicine conducts this test by interrogating the coding 
regions of 315 cancer-related genes and select introns from an additional 28 genes for 
alterations (FoundationOne, 2014). In contrast with many research-based studies, 
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FoundationOne does not require matched control samples from the patient to filter out 
germline information and instead removes any germline variants described in the 1000 
Genomes website (FoundationOne, 2014; Sun et al., 2014). While company studies have 
shown the accuracy rate of the method to be above 95% (Sun et al., 2014), there is the 
potential for germline results to remain in final profiling reports. 
 The FoundationOne team does not change its interpretation of tumor profiling results 
based on cancer type (FoundationOne, 2014). This panel and others like it test for genes 
associated with many different cancers, as tumors have been demonstrated to contain 
mutations associated with unrelated forms of cancer (Chmielecki et al., 2014; Lipson et al., 
2012). Although these mutations may not be the initial cause of the cancer, they may be 
powerful yet treatable driver mutations brought about as a consequence of cellular instability. 
For example, in the sequencing of one individual’s ovarian tumor, four treatable mutations 
not commonly associated with ovarian cancer were found using the FoundationOne cancer 
panel (Lipson et al., 2012). There has been a lot of success with this customized treatment 
approach, but it is still experimental. Drugs that successfully treat one type of cancer may not 
be able to do so with another type of cancer. For instance, the therapy that successfully 
treated BRAF driver mutations in patients with melanoma unfortunately did not have the 
same success treating BRAF driver mutations in patients with CRC (Tripathy, Harnden, 
Blackwell, & Robson, 2014). It is therefore important to consider novel treatment 
possibilities and opportunities. 
 Germline Mutations Detected in Tumor Profiling Studies 
 Approximately 30% of all cancers are caused by an unknown inherited component 
coupled with environmental carcinogens (Esteban-Jurado et al., 2014). Recent studies have 
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confirmed that genomic profiling of tumors is able to detect germline mutations and does so 
regularly. Schrader et al. (2015) of Memorial Sloan Kettering Cancer Center conducted a 
study in which 1,570 tumors of 68 different types (20% breast cancer; 14% non-small cell 
lung cancer; 66% other) were sequenced using a 341-gene cancer panel in a research setting; 
patients provided a matched blood sample as the germline control. Of the germline variants 
found, 16% were likely pathogenic. Approximately 101 (6.4%) of the 1,570 patients had at 
least one pathogenic germline mutation, and 807 had at least one VUS. In addition, 
approximately 13 (0.8%) patients displayed pathogenic germline variants not associated with 
their cancer type. For example, multiple patients with gastric cancer had pathogenic BRCA1 
mutations, and BRCA1 is not significantly associated with gastric cancer. These authors 
believe that germline mutations and variants may play a greater role in tumor development 
than currently recognized. It also demonstrates the availability of genetic counseling 
opportunities for 13 patients (with germline pathogenic variants) who most likely would not 
have been offered counseling or germline testing outside of the research setting. Because the 
germline mutations were found, these patients now have the option to pursue targeted 
screening, inform family members of associated risks, and take additional risk-lowering 
measures. For instance, a patient at increased risk of developing CRC may be recommended 
to take daily aspirin to combat this risk (Wang et al., 2015). Had this study been done in the 
clinical setting, it is possible that, based on current lab protocols, these germline variants 
would have been removed from the data or reported with minimal information such that 
potentially helpful management changes and disclosure guidelines may not have been shared 
with the patient. 
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 Another study conducted by Meric-Bernstam and colleagues (2016) of the University 
of Texas MD Anderson Cancer Center revealed similar results. In this study, 1,000 tumors of 
various types were sequenced using a 202-gene cancer panel in a research setting, and 
patients provided a matched control in the form of a blood sample. Meric-Bernstam et al. 
(2016) reported that 43 (~4.3%) out of the 1,000 patients had at least one pathogenic 
germline variant in 19 actionable cancer genes, with 16 (~1.6%) of these patients not meeting 
requirements for germline testing based on clinical information and family history alone. 
These numbers are relatively consistent with those of Schrader et al. (2015), further 
demonstrating that patients with cancer tend to have cancer-predisposing germline mutations 
at a much higher rate than the general population, whether or not those mutations are related 
to their type of cancer. Again, if these 16 patients were not tested in the research setting, it is 
likely, based on current recommendations, that they might never have been tested. 
 Need for Further Research 
 Few studies have examined the frequency of germline findings in research-based 
genomic profiling of multiple tumor types (Hall et al., 2015; Meric-Bernstam et al., 2016; 
Schrader et al., 2015). Building on these data, more research in the clinical context is needed, 
especially regarding the percentage of patients with germline findings and the percentage that 
are informed of these results and receive appropriate follow-up. 
 In addition, we are aware of no studies in the literature that assess the effectiveness of 
using public databases to gather information on reported tumor sequencing variants. 
Although the onus for comprehensive reporting is technically placed on the lab (Dumur, 
2014), identification of patients genetically predisposed to develop cancer is in practice done 
by clinicians, if at all. With over 900 different germline mutations known in the APC gene 
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alone (Esplin & Snyder, 2014), it may not be feasible for a clinician, such as a genetic 
counselor, to recognize these variants without referencing databases. Although a plethora of 
variant databases exists, they are often kept in silos, making it challenging for a clinician to 
cross-reference multiple databases at once (Rehm et al., 2015). Not only that, but some 
commercial labs may keep private databases that are not accessible to the public or most 
genetic counselors. This, coupled with patient demand for testing and workload of a busy 
clinician, may not allow for extensive germline variant research if not initially reported by 
the lab.  
Methods 
 Study Design 
 Through retrospective chart review, we compiled descriptive data of tumor profiling 
findings in a variety of tumor types by examining FoundationOne results reports. (A matched 
germline sample is not required in this profiling pipeline.) All reported variants were 
assessed for evidence of pathogenicity and for the potential of germline origin. Results of the 
descriptive analyses were used to devise indications for further review of patients’ personal 
and family histories and to identify cases appropriate for a referral for genetic counseling. 
 Sample Population 
 Our sample consists of de-identified FoundationOne tumor profiling reports from 
cancer patients treated at the University of Texas Southwestern Medical Center (UTSMC), 
Parkland Memorial Hospital and the Children's Medical Center of Dallas. Our sample is 
representative of a diverse patient population with a variety of tumor types in which tumor 
profiling was ordered with the purpose of identifying targeted cancer treatments. For the 
purpose of this project, non-solid tumor samples such as leukemia, bone marrow samples, 
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and samples which were listed as “unknown primary cancer” reports were not analyzed.  
 Procedures 
 Of the 405 total tumor profiling reports obtained, the 22 that were classified by 
FoundationOne as “failed” were discarded. In addition, leukemia, bone marrow disorder, and 
unknown primary cancer reports were also discarded, as we chose to examine solid tumors 
only. This resulted in a final sample size of 160 reports encompassing 66 different tumor 
types. 
 Reports were de-identified and assigned a sample ID. For each report, the following 
information was recorded: sample ID, tumor type, genes in which variants were found, 
specific variants found, and VUS or mutation status as classified by FoundationOne. We also 
noted the tumor types in our sample that are present in the ACMG and National Society of 
Genetic Counselors (NSGC)’s 2014 practice guideline for cancer predisposition referrals 
(Hampel et al., 2014). 
 All variants were cross referenced in the Clinvar public database, and the following 
information was recorded if an entry was found: ClinVar ID, clinical significance rating, date 
of search, total number of submissions, associated conditions, and number of germline 
submissions. 
 A list of selected genes associated with cancer predisposition was curated from 
existing genetic testing panels available at major commercial genetic testing companies 
(Table 1 in Appendix). Genes associated with Fanconi Anemia, a recessive cancer-
predisposing syndrome, were also included, bringing the total to 86 genes. All variants in our 
sample found in genes present in this curated list were noted for analysis, as they have each 
been associated with cancer predisposition. 
12 
 
 Measures and Data Analysis 
 Criteria for referrals to genetic counseling required either a tumor type from the 
ACMG/NSGC’s list of referral indications for cancer predisposition assessment (Hampel et 
al., 2014) or a mutation that has been previously observed in the germline as pathogenic, as 
noted in the ClinVar database, in a gene associated with cancer predisposition (Table 1). All 
variants labeled as “mutation” in FoundationOne reports were presumed to be pathogenic. 
All variants labeled as “variant of unknown significance” in FoundationOne reports were 
deemed suspicious for germline pathogenicity if they were described as “pathogenic,” “likely 
pathogenic,” or “risk factor” in ClinVar, regardless of other conflicting calls, and ClinVar 
reserves the “risk factor” designation “for variants that are interpreted not to cause a disorder 
but to increase the risk” (“Relating variation to medicine,” n.d.). All data were compiled in 
Microsoft Excel. 
 Results 
 Our sample of 160 tumor genomic profiling reports comprised 26 breast invasive 
ductal carcinoma (IDC) reports, 16 breast carcinoma (NOS) reports, 10 brain glioblastoma 
(GBM) reports, and 108 reports of 63 other tumor types, made up of 5 or fewer reports each. 
Mutations and VUSs were described by tumor type (Table 2 in Appendix), and reports 
averaged 4.24 mutations (0 - 13) and 9.8 VUSs (0 - 44) per individual tumor. 
 We examined reports for genetic counseling referral indications based on: (1) current 
ACMG/NSGC guidelines for tumor type, (2) mutations reported, and (3) VUSs reported. We 
then compared methods of detection. 
 After evaluating all 160 reports based on ACMG/NSGC guidelines for tumor type, it 
was determined that: 9 (6%) met criteria for a referral to genetic counseling based solely on 
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tumor type; 116 (72%) warranted assessment of personal and familial risk factors to 
determine whether a genetic counseling referral was appropriate based on tumor type; and 35 
(22%) had no indication for a referral to genetic counseling or further assessment based on 
tumor type (Hampel et al., 2014). 
 We examined our sample based on individual mutations and VUSs reported and 
described the utility of searching for variants in public database ClinVar (Table 3 in 
Appendix). Of the 679 individual mutations reported across our sample, 274 (40%) occurred 
in genes associated with cancer predisposition syndromes. Though we were unable to find 
222 (81%) of these 274 mutations in the ClinVar database, we were able to find 52 (19%) – 
with 48 (18%) reported as germline at least once and 42 (15%) reported as both germline and 
either “pathogenic,” “likely pathogenic,” or “risk factor” at least once – thereby identifying a 
group of mutations which, if present in the germline, would be concerning for a hereditary 
cancer predisposition syndrome. 
 We evaluated this group of at-risk mutations in the context of current ACMG/NSGC 
guidelines, in order to determine if current tumor type screening identified them. The 42 
mutations that were each reported at least once as both germline and on the pathogenic 
spectrum originated from 39 separate reports. Of these 39 reports: none met criteria for a 
referral to genetic counseling based solely on tumor type; 34 warranted assessment of 
personal and familial risk factors to determine whether a genetic counseling referral was 
appropriate based on tumor type; and 8 had no indication for a referral to genetic counseling 
or further assessment based on tumor type (Hampel et al., 2014). The latter 8 reports were 
described in further detail (Table 4 in Appendix). 
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 As the majority of mutations in cancer predisposition genes could not be cross-
referenced in ClinVar, we looked at the total sample of reports containing mutations in 
cancer predisposition genes for comparison of gene-focused methods (of screening for 
genetic counseling referral indications) with tumor type-focused methods. Of our 160 total 
reports, 127 reports (79%) carried mutations in genes associated with cancer predisposition. 
Of these reports, 5 (4%) met criteria for a referral to genetic counseling based solely on 
tumor type [adrenal gland cortical carcinoma (2), ovary sex-cord stromal tumor (1), pediatric 
soft tissue rhabdomyosarcoma alveolar (1), and soft tissue paraganglioma (1)]; 93 (73%) 
warranted assessment of personal and familial risk factors to determine whether a genetic 
counseling referral was appropriate based on tumor type; and 29 (23%) had no indication for 
a referral to genetic counseling or further assessment based on tumor type alone (Hampel et 
al., 2014). 
 We found that 104 reports (65%) had mutations in genes associated with cancer 
predisposition syndromes. When TP53 – a gene with mutations that are often somatic in 
origin – was excluded, the 79% of reports that contained mutations in genes associated with 
cancer predisposition decreased by 14% to the 65% that we now report (Olivier et al., 2010). 
 Of the 1,569 VUSs reported across our sample, 360 (23%) occurred in genes 
associated with cancer predisposition. Though we were unable to find 248 (69%) of these 
360 VUSs in ClinVar, we were able to find 112 (31%) – with 7 (2%) reported at least once as 
“pathogenic,” “likely pathogenic,” or “risk factor” [APC, BLM, BRIP1, CHEK2, PTEN, RET, 
and TSC1]. All 7 of these VUSs also had at least one germline entry in ClinVar. 
 We examined this group of VUSs in the context of ACMG/NSGC guidelines for 
tumor type. All 7 of these reports met criteria for assessment of personal and familial risk 
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factors to determine whether a genetic counseling referral was appropriate based on tumor 
type alone (Hampel et al., 2014). Further details of the reports were described (Table 5 in 
Appendix). 
 In summary, of the combined total of 2,248 mutations and VUSs reported in our 
sample, 55 (over 2%): were labeled in ClinVar at least once as “pathogenic,” “likely 
pathogenic,” or “risk factor;” had at least one germline entry in ClinVar; and occurred in a 
gene associated with cancer predisposition. 
Discussion 
 Results in the Context of Current Recommendations 
 The ACMG and NSGC currently recommend referral of individuals with certain 
tumor types (such as ovary) for genetic counseling – regardless of age, family history, and 
other factors – as well as further examination of personal and family medical history for 
other cancer types (such as breast) (Hampel et al., 2014). Given our findings, our study’s 
method of assessing cancer predisposition syndrome risk based on gene rather than on tumor 
type identified an additional group of patients with mutations that warrant evaluation for a 
cancer predisposition syndrome. This suggests that tumor profiling has the potential to 
identify high-risk patients that remain undetected by current screening recommendations for 
tumor type alone. It is therefore our opinion that screening for genetic counseling referral 
indications be both tumor type-focused and gene-focused when applicable. 
 Results in the Context of Similar Studies 
 As the present study did not include a matched germline control, we have no way of 
knowing which genetic alterations detected in our sample, if any, are germline in origin. 
However, previous studies can provide insight on the percentage of tumors in our sample that 
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might possess germline mutations in cancer predisposition genes. National statistics report 
that 5-10% of breast cancers and 5-10% of cancers in general are caused by a germline 
mutation (“Genetics of Breast and Gynecologic Cancers,” n.d.; “ The Genetics of Cancer,” 
n.d.), while tumor profiling studies that included a matched germline control have found 
germline mutations in cancer predisposition genes in 3-6% of reports (Jones et al., 2015; 
Meric-Bernstam et al., 2016; Schrader et al., 2015). These findings indicate that some 
germline mutations are detected through tumor profiling and that there is a need for tumor 
profiling reports generated without utilization of a matched germline control to be assessed 
for genetic counseling referral indications. 
 In the current study, we found that the majority of mutations in genes associated with 
cancer predisposition syndromes that were found in ClinVar had at least one germline entry. 
This suggests that the tumor profiling methods used in our study, much like previous studies, 
detected both germline and somatic findings. 
 Our study was unlike previous studies in that we did not have access to matched 
germline controls for our samples. We therefore had to do our best in estimating which 
mutations carried the highest risk of being associated with germline cancer predisposition. In 
the process, we discovered that tumor type-focused and gene-focused screening methods 
identify different patients as at-risk, with some overlap. As previously stated, we therefore 
believe that tumor profiling reports generated without utilization of a matched germline 
control should be reviewed based on individual mutations and variants found, in addition to 
tumor type. Genetic counseling can help to further clarify which patients may truly be at risk 




 Implications for Providers 
 Results of this study describe the clinical utility of searching public database ClinVar 
for mutations and VUSs cited in tumor profiling reports. Of alterations occurring in cancer 
predisposition genes, there was a 31% likelihood of finding a VUS and 19% likelihood of 
finding a mutation entered in ClinVar, and there was a 2% likelihood of finding a VUS and 
17% likelihood of finding a mutation with at least one entry on the pathogenic spectrum in 
ClinVar. These findings confirm that ClinVar is primarily a database of yet-to-be-categorized 
variants and that its calls may be inconsistent with those of FoundationOne. 
 The process of researching alterations occurring in cancer predisposition genes in 
ClinVar identified 8 patients in our study with mutations – which, if present in the germline, 
would be concerning for hereditary cancer predisposition syndromes – who had no indication 
for a referral to genetic counseling or further assessment based on tumor type. An additional 
7 patients with similarly concerning VUSs who would not have received referrals to genetic 
counseling based on tumor type alone were also identified. This suggests that there is value 
in researching both mutations and VUSs reported in tumor genomic profiling. 
 Depending on a provider’s caseload, familiarity with searching for genetic variants, 
knowledge of a patient’s personal and familial history, knowledge of this study, and other 
factors, she or he may decide differently on whether additional researching of variants in 
public databases is appropriate. This inconsistency in care decision-making may potentially 
diminish if tumor profiling companies change their reporting structure to include either: more 




 Another aspect of the study that is particularly relevant to providers is the fact that we 
had very limited knowledge about the patients whose tumor reports we reviewed, which may 
often be realistic in the clinical setting. One can imagine many situations in which having 
access to a patient’s detailed family and personal history may be difficult. For example, a 
patient may have limited knowledge of her or his family history or may have recently 
transferred care without previous medical documents available. In situations where access to 
a patient’s age, sex, and other personal factors is available, this information may quickly be 
used to rule in or out genetic counseling referrals. Other factors that are less likely to be 
known – such as ethnicity, cancer history, or family history – may also be used in quick 
assessments of genetic risk. It is in the absence of all such knowledge that the methods 
described in this study may prove most useful. 
 Study Limitations 
 The primary limitation of our study is that we are unable to confirm suspected 
germline mutations against a matched control. This is the inherent bias of tumor profiling 
conducted without matched control and the reason why the true percentage of germline 
mutations and variants in unknown in this study. 
 Another limitation was our usage of a single database – ClinVar – in gathering 
information on pathogenicity and germline origin. We did not use other methods such as 
functional assays, in silico predictors, or other variant databases. We acknowledge that there 
may be variants that are more accurately assessed in other gene-specific databases, and there 
may be stricter regulation of entries in non-public databases. ClinVar was primarily utilized 
in this study due to its status as a large public resource that is readily available to a variety of 
professionals who may be interpreting tumor profiling reports. Therefore, we anticipated that 
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our methods would have the potential to be widely replicated by professionals that wish to do 
so. 
 In addition, variants with only 1 pathogenic entry in ClinVar were categorized the 
same as variants with 10 pathogenic entries in ClinVar, as no feasible weight scale could be 
applied in analyses. This limitation allows variants that have been observed as pathogenic 
only once to be assigned to a risk category, which is a broad method of categorizing variants. 
This method, however, may be appropriate for clinicians looking to determine if genetic 
counseling is warranted based on tumor profiling results alone. 
 With regards to our list of genes associated with cancer predisposition, its large size 
exceeds the ACMG’s recommended list for reporting of incidental findings (Green et al. 
2013), leaving some genes without clear recommendations for medical management. Despite 
this, we felt that the curated list was representative of today’s market of germline testing 
products. As multi-gene cancer panels become more commonplace and our understanding of 
these genes expands, patients may opt for this more comprehensive method of testing 
following genetic counseling. This shift may result in more conversations and discoveries 
around panel gene findings. 
 Conclusions 
 Tumor profiling conducted without a matched germline control has the potential to 
detect germline mutations and therefore identify patients at increased risk for hereditary 
cancer predisposition syndromes. By assessing FoundationOne tumor profiling reports for 
mutations in genes associated with these syndromes, we identified patients who warrant 
further risk evaluation than current guidelines – based on tumor type alone – indicate. This 
suggests that tumor profiling reports generated without a matched germline control should be 
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reviewed based on individual mutations and VUSs found, in addition to tumor type. We also 
found – for some of the reported mutations and VUSs – supplemental information on 
pathogenicity and germline origin in public database ClinVar. This suggests that there is 
value in cross-referencing tumor profiling alterations in ClinVar, though calls were not 




























Table 1: Selected genes list (compilation of genes associated with hereditary cancer 
predisposition) 
ALK EGFR NF2 SDHAF2 
APC ENG PALB2 SDHB 
ATM EPCAM PAX5 SDHC 
AXIN2 FH PDGFRA SDHD 
BAP1 FLCN PHOX2B SMAD4 
BARD1 GATA2 PIK3CA SMARCA4 
BLM GPC3 PMS2 SMARCB1 
BMPR1A GREM1 POLD1 SMARCE1 
BRCA1 HOXB13 POLE STK11 
BRCA2 HRAS PRF1 SUFU 
BRIP1 KIT PRKAR1A TERC 
CASR MAX PTCH1 TERT 
CDC73 MEN1 PTEN TMEM127 
CDH1 MET PTPN11 TP53 
CDK4 MITF RAD50 TSC1 
CDKN1B MLH1 RAD51C TSC2 
CDKN1C MRE11A RAD51D TSHR 
CDKN2A MSH2 RB1 VHL 
CEBPA MSH6 RECQL4 WRN 
CHEK2 MUTYH RET WT1 
DICER1 NBN RUNX1  
DIS3L2 NF1 SDHA  
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Table 2: Mutation and VUS frequency by tumor type 
  Tumor type # of 
patients 












Of genes affected 
multiple times 
within tumor 
type group, gene 
most commonly 
affected (# of 
times affected) 
1 adrenal gland cortical 
carcinoma 
2 3 14 1.5 7 MLL2 (2) 
2 adrenal gland 
neuroblastoma 




1 4 12 4 12 None 
4 bladder adenocarcinoma 1 2 2 2 2 None 
5 bladder urothelial 
(transitional cell) 
carcinoma 
1 7 0 7 0 None 
6 bone chordoma 1 1 3 1 3 None 
7 bone osteosarcoma 1 2 8 2 8 SMARCB1 (2) 
8 brain anaplastic 
astrocytoma 
1 6 10 6 10 None 
9 brain astrocytoma 
pilocytic 
1 1 4 1 4 None 
10 brain astrocytoma 
pilomyxoid 
1 1 7 1 7 None 
11 brain ependymoma 1 2 4 2 4 MSH3 (2) 
12 brain glioblastoma 
(GBM) 
10 46 65 4.6 6.5 EGFR (7) 
13 brain glioma (NOS) 2 11 8 5.5 4 FGFR1 (2) 




15 breast carcinoma (NOS) 16 101 215 6.3 13.4 PIK3CA (9) 
16 breast invasive ductal 
carcinoma (IDC) 
26 306 534 11.8 20.5 TP53 (32) 
17 breast invasive lobular 
carcinoma (ILC) 
2 10 12 5 6 CDH1 (2), 
MED12 (2), 
PIK3CA (2) 
18 colon adenocarcinoma 
(CRC) 
2 20 57 10 28.5 PRKCI (4) 
19 esophagus 
adenocarcinoma 
3 16 50 5.3 16.7 LRP1B (3) 
20 eye intraocular 
melanoma 
1 6 4 6 4 BAP1 (2) 
21 head and neck squamous 
cell carcinoma (HNSCC) 
1 4 8 4 8 None 
22 kidney clear cell 
carcinoma 1 4 11 4 11 TET2 (2) 
23 kidney urothelial 
carcinoma 1 1 7 1 7 ERBB2 (2) 
24 liver cholangiocarcinoma 2 6 10 3 5 None 
25 liver hepatoblastoma 1 2 27 2 27 ASXL1 (2) 
26 liver hepatocellular 
carcinoma (HCC) 
1 2 22 2 22 None 
27 lung adenocarcinoma 4 18 31 4.5 7.7 BRCA2 (2), 
DDR2 (2), KRAS 
(2), MRE11A (2), 
NF1 (2), POLE 
(2), RICTOR (2), 
SPTA (2), STK11 
(2) 
28 lung large cell 
neuroendocrine 
carcinoma 
1 4 12 4 12 None 
29 lung small cell 
undifferentiated 
carcinoma 
3 8 61 2.7 20.3 TP53 (3) 
24 
 
30 lung squamous cell 
carcinoma (SCC) 
1 4 11 4 11 None 
31 myeloid sarcoma 1 1 10 1 10 None 
32 nasopharynx and 
paranasal sinuses 
esthesioneuroblastoma 
1 0 6 0 6 None 
33 ovary serous carcinoma 3 6 25 2 8.3 KRAS (2) 
34 ovary sex-cord stromal 
tumor 
1 2 7 2 7 DICER1 (2) 
35 pancreas ductal 
adenocarcinoma 
5 19 35 3.8 7 KRAS (5), TP53 
(5) 
36 pancreas solid and 
papillary tumor 
1 3 2 3 2 None 
37 pancreatobiliary 
carcinoma (NOS) 
1 3 7 3 7 None 
38 pediatric adrenal gland 
neuroblastoma 
1 6 10 6 10 ALK (5) 
39 pediatric brain 
astrocytoma 
1 6 15 6 15 BRD4 (2) 
40 pediatric brain 
astrocytoma pilomyxoid 
1 1 6 1 6 None 
41 pediatric liver 
hepatoblastoma 
1 2 11 2 11 None 
42 pediatric soft tissue 
rhabdomyosarcoma 
alveolar 
1 2 11 2 11 STAT6 (2) 
43 pediatric soft tissue 
sarcoma (NOS) 
1 1 7 1 7 WDR90 (2) 
44 penis squamous cell 
carcinoma (SCC) 
1 4 18 4 18 RANBP2 (2), RET 
(2) 
45 rectum adenocarcinoma 
(CRC) 
1 3 3 3 3 None 
46 salivary gland acinic cell 
tumor 
1 1 0 1 0 None 
25 
 
47 skin adnexal carcinoma 1 6 11 6 11 None 
48 skin basal cell carcinoma 1 5 22 5 22 LRP1B (3) 
49 skin melanoma 2 10 50 5 25 ALK (3), PRKDC 
(3) 
50 skin squamous cell 
carcinoma (SCC) 
2 13 17 6.5 8.5 TP53 (6) 
51 soft tissue angiosarcoma 1 0 11 0 11 None 
52 soft tissue 
chondrosarcoma 
3 9 36 3 12 BRCA2 (2), MLL3 
(2), PRKAR1A (2) 
53 soft tissue ewing 
sarcoma 
1 2 7 2 7 None 
54 soft tissue 
leiomyosarcoma 
4 11 26 2.7 6.5 TP53 (3) 
55 soft tissue liposarcoma 1 4 13 4 13 None 
56 soft tissue malignant 
peripheral nerve sheath 
tumor (MPNST) 





57 soft tissue neuroblastoma 4 4 21 1 5.2 ATM (2), PIK3CG 
(2) 
58 soft tissue paraganglioma 1 2 3 2 3 ATRX (2) 
59 soft tissue 
rhabdomyosarcoma 
(NOS) 
2 9 24 4.5 12 EP300 (2), 
FANCD2 (2), 
MKI67 (2) 
60 soft tissue sarcoma 
(NOS) 
4 7 33 1.7 8.2 GPR124 (2) 
61 soft tissue schwannoma 1 2 6 2 6 None 
62 stomach adenocarcinoma 
diffuse type 
1 3 7 3 7 CDH1 (2) 
26 
 
63 thyroid anaplastic 
carcinoma 
5 31 46 6.2 9.2 TP53 (11) 
64 unknown primary 
melanoma 
5 27 41 5.4 8.2 BAP1 (2), BRAF 
(2), FAM123B 
(2), FGF3 (2), 
HGF (2), KDR 
(2), MAP2K1 (2), 
MCL1 (2), MYC 
(2), RUNX1T1 (2) 
65 unknown primary 
urothelial carcinoma 
1 5 9 5 9 None 
66 urethra squamous cell 
carcinoma (SCC) 

























Table 3: ClinVar reporting of FoundationOne mutations and VUSs 
  Total # Total # (%) in 
selected genes 
Total # (%) of 
those in selected 
genes that were 
found in ClinVar 
Total # (%) of those in 
selected genes that were 
cited ≥1 times as 
pathogenic, likely 
pathogenic, or risk 
factor in ClinVar 
Total # (%) of 
those in 
selected genes 
that were cited 
as benign or 
likely benign 
only in ClinVar 
Mutations 679 274 (40.4) 52 (19) 46 (17) 0 (0) 

























Table 4: Selected reports with mutations in cancer predisposition genes and no 
indications for referrals to genetic counseling or further assessment based on tumor 
type alone 





Total # of 
submissions 
in ClinVar 






1 bladder urothelial 
(transitional cell) 
carcinoma 
PIK3CA c.1624G>A 4 1 Pathogenic 
2 liver 
cholangiocarcinoma 
APC c.3920T>A 8 8 Conflicting 
interpretations of 
pathogenicity, not 






BRCA2 c.476-1G>A 2 2 Pathogenic 
4 penis squamous cell 
carcinoma (SCC) 
RET c.2410G>A 4 4 Pathogenic 
5 skin squamous cell 
carcinoma (SCC) 





6 skin squamous cell 
carcinoma (SCC) 





7 soft tissue 
neuroblastoma 
PTPN11 c.1508G>C 1 1 Pathogenic 
8 soft tissue 
neuroblastoma 










Table 5: Selected reports with VUSs in cancer predisposition genes and tumor types 
meeting criteria for assessment of personal and familial risk factors 





Total # of 
submissions 
in ClinVar 






1 breast invasive 
ductal 
carcinoma (IDC) 
APC c.388A>G 4 4 Conflicting interpretations 
of pathogenicity; Likely 
pathogenic (1); Pathogenic 
(4); Uncertain significance 
(1) 
2 breast invasive 
ductal 
carcinoma (IDC) 
BLM c.2015A>G 1 1 Likely pathogenic 
3 breast invasive 
ductal 
carcinoma (IDC) 
BRIP1 c.1045G>C 3 3 Conflicting interpretations 
of pathogenicity, not 
provided; Pathogenic (1); 
Uncertain significance (1) 
4 breast invasive 
ductal 
carcinoma (IDC) 
CHEK2 c.1283C>T 4 4 Pathogenic, risk factor 
5 lung squamous 
cell carcinoma 
(SCC) 




RET c.2372A>T 14 14 Conflicting interpretations 
of pathogenicity; Benign 
(2); Likely benign (2); 





TSC1 c.2194C>T 9 9 Conflicting interpretations 
of pathogenicity, not 
provided; Benign (3); 
Likely benign (2); 
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